Used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), especially in patients resistant to other therapies. It acts as a tyrosine kinase inhibitor, targeting the BCR-ABL fusion protein, including the T315I mutation that is resistant to many other kinase inhibitors. Ponatinib hydrochloride helps suppress cancer cell growth and proliferation by blocking signaling pathways involved in tumor development. It is prescribed when other treatments have failed or are not suitable, offering a critical option for patients with limited alternatives.